Shopping Cart

Remove All

Your shopping cart is currently empty

Proceed to checkout Continue shopping

Mifamurtide

Name: Mifamurtide
Brand: TargetMol
SKU: T12037
Rating: 4.5 (1 reviews)

(Synonyms: MTP-PE, L-MTP-PE, CGP19835, CGP 19835) Copy Product Info

🥰Excellent

Synonyms: MTP-PE, L-MTP-PE, CGP19835, CGP 19835

Catalog No. T12037 Copy Product Info

🥰Excellent

Mifamurtide (MTP-PE), an analog of muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide (MTP-PE) is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide (MTP-PE) is used in immunology and rare disease research, including osteosarcoma-related experimental models, where Mifamurtide (MTP-PE) is applied to study innate immune receptor activation, macrophage polarization, and NOD2-associated signaling pathways in cellular immune response systems.

Cas No. 83461-56-7

Pack Size	Price	USA Stock	Global Stock	Quantity
1 mg	$1,440	Inquiry	Inquiry

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

Custom-made molecule. TargetMol’s expert synthesis team delivers cost-effective solutions. Contact us for inquiries. Committed to serving you.However, due to objective factors, there is a small probability that the synthesis may not be successful during the R&D process. We appreciate your understanding.

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Appearance:Solid

Color:White

Resource Download

COA

Product Introduction

Bioactivity

Description	Mifamurtide (MTP-PE), an analog of muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide (MTP-PE) is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide (MTP-PE) is used in immunology and rare disease research, including osteosarcoma-related experimental models, where Mifamurtide (MTP-PE) is applied to study innate immune receptor activation, macrophage polarization, and NOD2-associated signaling pathways in cellular immune response systems.
In vivo	Method:Thirty-three subjects were enrolled, including mild renal impairment (n=9), moderate renal impairment (n=8), and healthy subjects (n=16), to evaluate mifamurtide pharmacokinetics, pharmacodynamics, and safety across renal function groups. Result:Geometric mean (%CV) AUCinf for total mifamurtide was 89.5 (58.1), 94.8 (27.8), 85.1 (29.0), and 95.4 (18.1) nm·h in mild renal impairment, mild-matched healthy, moderate renal impairment, and moderate-matched healthy groups, respectively. Mifamurtide clearance was not correlated with CLcr, estimated GFR, or iohexol clearance (all r² < 0.01). AUCinf of free mifamurtide was similar across renal function groups. No apparent differences were observed in serum pharmacodynamic parameters (IL-6, TNF-α AUEClast and CRP Emax). No grade ≥3 or serious adverse events were reported.
Synonyms	MTP-PE, L-MTP-PE, CGP19835, CGP 19835

Chemical Properties

Molecular Weight	1237.50
Formula	C₅₉H₁₀₉N₆O₁₉P
Cas No.	83461-56-7
Smiles	[C@H]([C@@H](NC(C)=O)C=O)(O[C@@H](C(N[C@H](C(N[C@H](CCC(N[C@H](C(NCCOP(OC[C@H](OC(CCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCC)=O)(=O)O)=O)C)=O)C(N)=O)=O)C)=O)C)[C@@H]([C@@H](CO)O)O
Relative Density.	1.152g/cm3
Sequence	MurNAc-Ala-D-Glu-dipalmitoyl-PE
Sequence Short	MurNAc-AE-DPPE

Storage & Solubility Information

Storage

Store under nitrogen, Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 80 mg/mL (64.65 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.30 mg/mL (2.67 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	0.8081 mL	4.0404 mL	8.0808 mL	40.4040 mL
5 mM	0.1616 mL	0.8081 mL	1.6162 mL	8.0808 mL
10 mM	0.0808 mL	0.4040 mL	0.8081 mL	4.0404 mL
20 mM	0.0404 mL	0.2020 mL	0.4040 mL	2.0202 mL
50 mM	0.0162 mL	0.0808 mL	0.1616 mL	0.8081 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc